Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
Stelljes M, Advani AS, DeAngelo DJ, Wang T, Neuhof A, Vandendries E, Kantarjian H, Jabbour E. Stelljes M, et al. Among authors: neuhof a. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e836-e843. doi: 10.1016/j.clml.2022.04.022. Epub 2022 Apr 27. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35643855 Free article. Clinical Trial.
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Kantarjian HM, Stock W, Cassaday RD, DeAngelo DJ, Jabbour E, O'Brien SM, Stelljes M, Wang T, Paccagnella ML, Nguyen K, Sleight B, Vandendries E, Neuhof A, Laird AD, Advani AS. Kantarjian HM, et al. Among authors: neuhof a. Clin Cancer Res. 2021 May 15;27(10):2742-2754. doi: 10.1158/1078-0432.CCR-20-2399. Epub 2021 Feb 18. Clin Cancer Res. 2021. PMID: 33602684
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Cassaday RD, Marks DI, DeAngelo DJ, Jabbour EJ, Advani AS, O'Brien S, Wang T, Neuhof A, Vandendries E, Kantarjian HM, Stock W, Stelljes M. Cassaday RD, et al. Among authors: neuhof a. Br J Haematol. 2020 Nov;191(3):e77-e81. doi: 10.1111/bjh.17029. Epub 2020 Aug 17. Br J Haematol. 2020. PMID: 32805058 Free article. No abstract available.
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
Jabbour E, Stelljes M, Advani AS, DeAngelo DJ, Gökbuget N, Marks DI, Stock W, O'Brien S, Cassaday RD, Wang T, Neuhof A, Vandendries E, Kantarjian H. Jabbour E, et al. Among authors: neuhof a. Leuk Lymphoma. 2020 Aug;61(8):2012-2015. doi: 10.1080/10428194.2020.1751839. Epub 2020 May 7. Leuk Lymphoma. 2020. PMID: 32378440 No abstract available.
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E, Gökbuget N, Advani A, Stelljes M, Stock W, Liedtke M, Martinelli G, O'Brien S, Wang T, Laird AD, Vandendries E, Neuhof A, Nguyen K, Dakappagari N, DeAngelo DJ, Kantarjian H. Jabbour E, et al. Among authors: neuhof a. Leuk Res. 2020 Jan;88:106283. doi: 10.1016/j.leukres.2019.106283. Epub 2019 Nov 25. Leuk Res. 2020. PMID: 31790983 Free article. Clinical Trial.
18 results